Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Intimal Arteritis and Microvascular Inflammation Are Associated With Inferior Kidney Graft Outcome, Regardless of Donor-Specific Antibodies

M. Novotny, P. Hruba, M. Kment, L. Voska, K. Kabrtova, A. Slavcev, O. Viklicky

. 2021 ; 8 (-) : 781206. [pub] 20211208

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22001092

Background: The prognostic role of intimal arteritis of kidney allografts in donor-specific antibody negative (DSA-) antibody-mediated rejection (ABMR) remains unclear. Methods: Seventy-two out of 881 patients who had undergone kidney transplantation from 2014 to 2017 exhibited intimal arteritis in biopsies performed during the first 12 months. In 26 DSA negative cases, the intimal arteritis was accompanied by tubulointerstitial inflammation as part of T cell-mediated vascular rejection (TCMRV, N = 26); intimal arteritis along with microvascular inflammation occurred in 29 DSA negative (ABMRV/DSA-) and 19 DSA positive cases (ABMRV, DSA+, N = 17). In 60 (83%) patients with intimal arteritis, the surveillance biopsies after antirejection therapy were performed. Hundred and two patients with non-vascular ABMR with DSA (ABMR/DSA+, N = 55) and without DSA (ABMR/DSA-, N = 47) served as controls. Time to transplant glomerulopathy (TG) and graft failure were the study endpoints. Results: Transplant glomerulopathy -free survival at 36 months was 100% in TCMRV, 85% in ABMR/DSA-, 65% in ABMRV/DSA-, 54% in ABMR/DSA+ and 31% in ABMRV/DSA+ (log rank p < 0.001). Death-censored graft survival at 36 months was 98% in ABMR/DSA-, 96% in TCMRV, 86% in ABMRV/DSA-, 79% in ABMR/DSA+, and 64% in ABMRV/DSA+ group (log rank p = 0.001). In surveillance biopsies, the resolution of rejection was found in 19 (90%) TCMRV, 14 (58%) ABMRV/DSA-, and only 4 (27%) ABMRV/DSA+ patients (p = 0.006). In the multivariable model, intimal arteritis as part of ABMR represented a significant risk for TG development (HR 2.1, 95% CI 1.2-3.8; p = 0.012) regardless of DSA status but not for graft failure at 36 months. Conclusions: Intimal arteritis as part of ABMR represented a risk for early development of TG regardless of the presence or absence of DSA. Intimal arteritis in DSA positive ABMR represented the high-risk phenotype.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22001092
003      
CZ-PrNML
005      
20220112153500.0
007      
ta
008      
220107s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fmed.2021.781206 $2 doi
035    __
$a (PubMed)34957155
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Novotny, Marek $u Department of Nephrology, Transplant Centre, Institute for Clinical and Experimental Medicine, Prague, Czechia $u Institute of Physiology, First Medical Faculty, Charles University, Prague, Czechia
245    10
$a Intimal Arteritis and Microvascular Inflammation Are Associated With Inferior Kidney Graft Outcome, Regardless of Donor-Specific Antibodies / $c M. Novotny, P. Hruba, M. Kment, L. Voska, K. Kabrtova, A. Slavcev, O. Viklicky
520    9_
$a Background: The prognostic role of intimal arteritis of kidney allografts in donor-specific antibody negative (DSA-) antibody-mediated rejection (ABMR) remains unclear. Methods: Seventy-two out of 881 patients who had undergone kidney transplantation from 2014 to 2017 exhibited intimal arteritis in biopsies performed during the first 12 months. In 26 DSA negative cases, the intimal arteritis was accompanied by tubulointerstitial inflammation as part of T cell-mediated vascular rejection (TCMRV, N = 26); intimal arteritis along with microvascular inflammation occurred in 29 DSA negative (ABMRV/DSA-) and 19 DSA positive cases (ABMRV, DSA+, N = 17). In 60 (83%) patients with intimal arteritis, the surveillance biopsies after antirejection therapy were performed. Hundred and two patients with non-vascular ABMR with DSA (ABMR/DSA+, N = 55) and without DSA (ABMR/DSA-, N = 47) served as controls. Time to transplant glomerulopathy (TG) and graft failure were the study endpoints. Results: Transplant glomerulopathy -free survival at 36 months was 100% in TCMRV, 85% in ABMR/DSA-, 65% in ABMRV/DSA-, 54% in ABMR/DSA+ and 31% in ABMRV/DSA+ (log rank p < 0.001). Death-censored graft survival at 36 months was 98% in ABMR/DSA-, 96% in TCMRV, 86% in ABMRV/DSA-, 79% in ABMR/DSA+, and 64% in ABMRV/DSA+ group (log rank p = 0.001). In surveillance biopsies, the resolution of rejection was found in 19 (90%) TCMRV, 14 (58%) ABMRV/DSA-, and only 4 (27%) ABMRV/DSA+ patients (p = 0.006). In the multivariable model, intimal arteritis as part of ABMR represented a significant risk for TG development (HR 2.1, 95% CI 1.2-3.8; p = 0.012) regardless of DSA status but not for graft failure at 36 months. Conclusions: Intimal arteritis as part of ABMR represented a risk for early development of TG regardless of the presence or absence of DSA. Intimal arteritis in DSA positive ABMR represented the high-risk phenotype.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Hruba, Petra $u Transplant Laboratory, Transplant Centre, Institute for Clinical and Experimental Medicine, Prague, Czechia
700    1_
$a Kment, Martin $u Department of Clinical and Transplant Pathology, Institute for Clinical and Experimental Medicine, Prague, Czechia
700    1_
$a Voska, Ludek $u Department of Clinical and Transplant Pathology, Institute for Clinical and Experimental Medicine, Prague, Czechia
700    1_
$a Kabrtova, Katerina $u Department of Immunogenetics, Institute for Clinical and Experimental Medicine, Prague, Czechia
700    1_
$a Slavcev, Antonij $u Department of Immunogenetics, Institute for Clinical and Experimental Medicine, Prague, Czechia
700    1_
$a Viklicky, Ondrej $u Department of Nephrology, Transplant Centre, Institute for Clinical and Experimental Medicine, Prague, Czechia $u Institute of Physiology, First Medical Faculty, Charles University, Prague, Czechia $u Transplant Laboratory, Transplant Centre, Institute for Clinical and Experimental Medicine, Prague, Czechia
773    0_
$w MED00188756 $t Frontiers in medicine $x 2296-858X $g Roč. 8, č. - (2021), s. 781206
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34957155 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20220107 $b ABA008
991    __
$a 20220112153456 $b ABA008
999    __
$a ind $b bmc $g 1745360 $s 1152239
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 8 $c - $d 781206 $e 20211208 $i 2296-858X $m Frontiers in medicine $n Front. med. $x MED00188756
LZP    __
$a Pubmed-20220107

Najít záznam

Citační ukazatele

Možnosti archivace